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THE HUMAN PAPILLOMAVIRUS VACCINES
 Genital human papillomavirus (HPV) infection 
is the most common sexually transmitted infection 
(STI) among sexually active couples. Its annual 
incidence is approximately 5.5 million. Overall, an 
estimated 75% of sexually active men and women 
have been exposed to HPV at some point in their 
lives. HPV-16 and -18 account for about 70% of 
cancers of the cervix, vagina and anus, and for 
about 30%-40% of cancers of the vulva, penis and 
orophaynx. Cancer of the cervix uteri is the second 
most cancer among women worldwide. Cancer of 
the penis is a rare cancer, accounting for less than 
0.5% of cancers in men. 
 Spontaneous clearance of HPV infection is 
accompanied by humoral and cellular immune 
response against virus-specific antigens. Two 
vaccines, prophylactic and therapeutic ones, are 
considered. Prophylactic vaccines use L1 and L2 
capsid proteins to induce production of conforma-
tionally-specific antibodies. They block HPV infec-
tion. Lone L1 and L2 proteins self-assemble into 
a capsid that is identical to the complete virion. 
In this way, an antibody-mediated response is in-
duced before the body actually comes into con-
tact with the live virion. Therapeutic vaccines are 
being developed to protect HPV-positive persons 
against tumor development. For these vaccines, 
researchers are targeting the activity of the E6 and 
E7 oncoproteines.
 On June 8, 2006, the U.S. Food and Drug Ad-
ministration (FDA) approved an HPV vaccine for 
clinical use. The HPV vaccine that has been ap-
proved is the quadrivalent vaccine that consists 
of recombinant viral-like particles (VLPs) of HPV 
6, 11, 16, 18 mixed with an aluminum-containing 
adjuvant. It is manufactured by Merck & Co., Inc. 
and sold under the name of Gardasil.
 The new vaccine is approved for use in females 
9-26 years of age. The primary target population 
for vaccination should be females aged 11-12 
years. However, vaccination can be given to girls 
as young as 9 years of age. Vaccination can re-
ceive women aged 13-26 years who have been 
sexually active. There are still no data on the vac-
cine efficacy in women older than 26, and currently 
no data to demonstrate the efficacy of vaccination 
in males; male subjects should not be vaccinated 
until such data become available.
 The vaccine is to be administered intramuscu-
larly either into the deltoid muscle of the arm or 
the high anteriolateral area of the leg. Each patient 
receives three 0.5 mL doses given according to 
the following schedule: first dose is given at the 
elected date, second dose two months after the 
first dose, and third dose six months after the first 
dose. According to statements from Merck, the list 
price of the vaccine is 120 USD per dose.
 GlaxoSmithKline is now conducting a phase III 
trial of a bivalent (HPV 16, 18) vaccine, and it is go-
ing to be presented under the name of Cervarix®. 
Similar results to those obtained with the quadri-
valent HPV vaccine have been reported with the 
bivalent vaccine. It is expected to be released in 
June next year.
 Evaluation of the HPV vaccine efficiency in 
preventing dysplasia and cancer has been recom-
mended as a globally accepted endpoint for popu-
lation based studies. 
Suzana Ljubojević, MD, PhD
References
1. Parkin DM, Bray F. The burden of HPV-related 
cancers. Vaccine 2006:24S3:S/11-S3/25.
2. Inglis S, Shaw A, Koenig S. HPV vaccines: 
commercial research & development. Vaccine 
2006;24S3:S3/99-S3/105. 
3. Harper DM, Franco EL, Wheeler C, Moscicki 
AB, Romanowski B, Roteli-Martinus CM, et 
al. Sustained efficacy up to 4.5 years of a bi-
valent L1 virus-like particle vaccine against 
human papillomavirus types 16 and 18: fol-
low-up from randomized control trial. Lancet 
2006;367:1247-55.
4. National Cancer Institute. Cervical cancer phy-
sician data query (PDQ®): prevention (health 
professional version) (online) http://cancer.gov/ 
(accessed 2006 September 5).
5. Gardasil package insert. Released June 2006. 
http://www.fda.gov/cber/label/hpvmer060806 
LB.htm. (Accessed 2006 September 5).
ACTA DERMATOVENEROLOGICA CROATICA
